Tempest Therapeutics’ (TPST) Neutral Rating Reiterated at HC Wainwright

HC Wainwright reissued their neutral rating on shares of Tempest Therapeutics (NASDAQ:TPST) in a research report report published on Thursday, MarketBeat Ratings reports. They currently have a $16.00 price target on the stock.

Separately, Scotiabank reissued a “sector perform” rating and set a $9.00 price target (up from $7.00) on shares of Tempest Therapeutics in a report on Thursday.

Tempest Therapeutics Stock Performance

NASDAQ TPST opened at $6.22 on Thursday. The firm has a market capitalization of $21.89 million, a P/E ratio of -4.07 and a beta of -2.34. The stock has a 50-day simple moving average of $10.23 and a two-hundred day simple moving average of $11.90. Tempest Therapeutics has a fifty-two week low of $5.35 and a fifty-two week high of $50.18.

Tempest Therapeutics (NASDAQ:TPST) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($4.03) earnings per share for the quarter, missing the consensus estimate of ($3.12) by ($0.91). The company had revenue of $0.49 million during the quarter. As a group, analysts forecast that Tempest Therapeutics will post -1.39 earnings per share for the current year.

Institutional Trading of Tempest Therapeutics

Several institutional investors have recently bought and sold shares of TPST. Versant Venture Management LLC purchased a new position in shares of Tempest Therapeutics during the 4th quarter valued at approximately $2,927,000. Jane Street Group LLC acquired a new position in Tempest Therapeutics during the fourth quarter worth $411,000. Geode Capital Management LLC lifted its holdings in Tempest Therapeutics by 61.0% during the fourth quarter. Geode Capital Management LLC now owns 354,276 shares of the company’s stock valued at $296,000 after purchasing an additional 134,209 shares in the last quarter. Millennium Management LLC acquired a new stake in shares of Tempest Therapeutics in the fourth quarter valued at about $158,000. Finally, XTX Topco Ltd increased its stake in shares of Tempest Therapeutics by 570.3% during the fourth quarter. XTX Topco Ltd now owns 160,807 shares of the company’s stock worth $134,000 after purchasing an additional 136,818 shares in the last quarter. 22.52% of the stock is owned by institutional investors and hedge funds.

Tempest Therapeutics Company Profile

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.